Sivatharshini Ramalingam
Overview
Explore the profile of Sivatharshini Ramalingam including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
45
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tong J, Senechal I, Ramalingam S, Lyon A
Br J Hosp Med (Lond)
. 2025 Jan;
86(1):1-21.
PMID: 39862029
The burdens of cardiovascular (CV) diseases and cardiotoxic side effects of cancer treatment in oncology patients are increasing in parallel. The European Society of Cardiology (ESC) 2022 Cardio-Oncology guidelines recommend...
2.
Raisi-Estabragh Z, Murphy A, Ramalingam S, Scherrer-Crosbie M, Lopez-Fernandez T, Reynolds K, et al.
JACC CardioOncol
. 2024 Oct;
6(5):631-654.
PMID: 39479317
Baseline cardiovascular assessment before the initiation of potentially cardiotoxic cancer therapies is a key component of cardio-oncology, aiming to reduce cardiovascular complications and morbidity in patients and survivors. Recent clinical...
3.
Senechal I, Andres M, Tong J, Ramalingam S, Nazir M, Rosen S, et al.
Curr Oncol Rep
. 2024 Sep;
26(11):1431-1441.
PMID: 39316222
Purpose Of Review: In this review article we describe the cardiovascular adverse events associated with BRAF and MEK inhibitors as well as their pathophysiologic mechanisms and provide up to date...
4.
Tong J, Vogiatzakis N, Andres M, Senechal I, Badr A, Ramalingam S, et al.
Cardiooncology
. 2024 Aug;
10(1):53.
PMID: 39175028
Background: Immune checkpoint inhibitor (ICI) myocarditis is an uncommon but potentially fatal complication of immunotherapy. Cardiac imaging is essential to make timely diagnoses as there are critical downstream implications for...
5.
Tocchetti C, Farmakis D, Koop Y, Andres M, Couch L, Formisano L, et al.
Eur J Heart Fail
. 2024 Aug;
26(10):2055-2076.
PMID: 39087551
The advent of immunological therapies has revolutionized the treatment of solid and haematological cancers over the last decade. Licensed therapies which activate the immune system to target cancer cells can...
6.
Andres M, Murphy T, Poku N, Nazir M, Ramalingam S, Baksi J, et al.
JACC CardioOncol
. 2024 May;
6(2):310-312.
PMID: 38774020
No abstract available.
7.
Senechal I, Vogiatzakis N, Andres M, Tong J, Ramalingam S, Rosen S, et al.
Cardiooncology
. 2024 Apr;
10(1):23.
PMID: 38605419
Panitumumab is a human immunoglobulin monoclonal antibody designed to target the epidermal growth factor receptor (EGFR) which is used in the treatment of metastatic colorectal cancer alone or in combination...
8.
Senechal I, Andres M, Tong J, Perone Y, Ramalingam S, Nazir M, et al.
Cardiooncology
. 2024 Mar;
10(1):14.
PMID: 38454509
Long-term anti-HER2 therapy in metastatic HER2 + cancers is increasing, but data about the incidence and risk factors for developing late Cancer therapy-related cardiac dysfunction (CTRCD) are missing. We conducted...
9.
Larkin J, Beland C, Ramalingam S, Lyon A
Nature
. 2024 Mar;
627(8002):38.
PMID: 38443637
No abstract available.
10.
Talukder S, Ghose A, Chakraborty T, Olsson-Brown A, Ramalingam S, Rosen S, et al.
Int J Cardiol Heart Vasc
. 2023 Oct;
49:101278.
PMID: 37842144
No abstract available.